

## Serum Institute, Aragen Bio announce vaccine development collaboration

09 January 2020 | News

### Aragen will leverage its expertise in the RapTr™ platform



Aragen Bioscience, Inc., a subsidiary of GVK BIO and one of the leading preclinical ORCs specializing in the development of monoclonal antibodies and other products based on large molecules, and Serum Institute of India Pvt.Ltd. (SIPL), the world's largest vaccine manufacturer, are pleased to announce their collaboration on the development of multiple stable cell lines to support Serum's HIV program.

This partnership between Serum and Aragen brings together two organizations committed to "Accelerating R&D in the life sciences", with the objective of developing affordable monoclonal antibodies that improve the quality of life for human beings.

Aragen will leverage its expertise in the RapTr™ platform, which uses proprietary vectors and CHO DG44 host cells to develop cell lines. Combined with the analytical platform, Aragen is preparing to supply Serum with high extraction cell lines allowing Serum to rapidly advance its program towards manufacturing. With a proven experience of more than 50 years in the development of affordable drugs, Serum will focus its efforts on the transformation of these innovative molecules into vaccines or decisive treatments that treat and prevent diseases around the world.

"We are delighted to partner with the world leader in vaccines," said Manni Kantipudi, President of Aragen and President and CEO of GVK BIO. "The Aragen team is renowned worldwide for its ability to clone and express complex proteins. Through this collaboration with Serum, we hope to use this expertise to develop and deliver affordable organic products."

"SIPL is very happy to collaborate with Aragen. SIPL is already collaborating with IAVI and Scripps Research to discover innovative monoclonal antibodies against HIV. Thanks to our manufacturing capabilities and this collaboration to develop stable cell lines with Aragen, SIPL will be able to provide cost-effective monoclonal antibodies against HIV for developing and developed countries," said Mr. Adar Poonawalla, CEO of SIPL.